Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Northern Biologics was a private biotechnology company (2014-2020) dedicated to the discovery and development of novel, first-in-class therapeutic antibodies targeting the tumor microenvironment to treat cancer and fibrosis. Spun out from the University of Toronto and University Health Network, it leveraged deep expertise in antibody development and cancer biology. Its lead programs explored innovative mechanisms to modulate the immune system and stromal components within tumors. In December 2020, Boehringer Ingelheim acquired key preclinical assets from Northern Biologics, which subsequently led to the wind-down of Northern Biologics' operations.
Primarily served as the hub for research and development, drug discovery, and corporate operations for its antibody therapeutic programs.
Operated within JLABS @ Toronto, part of the MaRS Discovery District, providing access to advanced shared laboratory facilities, modern office space, and a vibrant biotech innovation ecosystem.
As a venture-backed biotech, the work culture was likely characterized by scientific innovation, a results-driven approach, and collaboration, further enhanced by its presence in the JLABS incubator environment.
The headquarters was central to Northern Biologics' efforts in pioneering novel antibody therapeutics, strategically positioned within Toronto's prominent life sciences research community and benefiting from the comprehensive resources of the MaRS Discovery District.
While primarily based and focused on research and development in Canada, Northern Biologics' global engagement during its operational years included collaborations with international research entities, participation in global scientific conferences, and interactions with multinational pharmaceutical companies for potential partnerships and licensing, as evidenced by its eventual asset acquisition by the global firm Boehringer Ingelheim. The company did not maintain its own international offices.
661 University Ave, Suite 440 (JLABS @ Toronto)
Toronto
Ontario
Canada
Address: N/A
Operations were centralized in Toronto to leverage the local biotech ecosystem and maintain a focused R&D effort, typical for a company of its size and stage.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Northern Biologics' leadership includes:
Northern Biologics has been backed by several prominent investors over the years, including:
Following the December 2020 acquisition of its key assets by Boehringer Ingelheim, Northern Biologics commenced a wind-down of its operations. This period saw the transition of its executive team as their roles concluded with the company's operational cessation. No new executive hires were made in the 12 months leading up to and during the wind-down.
Discover the tools Northern Biologics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The following email format information for Northern Biologics is based on common industry patterns and is historical, as the company is no longer operational and its domain is inactive.
[first_initial][last]@northernbiologics.com
Format
pvickers@northernbiologics.com (example, not active)
Example
0 (company no longer operational, domain inactive; historically, common formats like this had an estimated 75-85% success rate)%
Success rate
Boehringer Ingelheim • December 1, 2020
Boehringer Ingelheim announced the acquisition of Northern Biologics Inc.’s preclinical pipeline of antibodies targeting the tumor microenvironment, significantly expanding Boehringer Ingelheim's immuno-oncology pipeline....more
GlobeNewswire • December 1, 2020
Northern Biologics confirmed that following the sale of its lead preclinical assets to Boehringer Ingelheim, it would initiate an orderly wind-down of its remaining operations, aiming to provide a return to its shareholders....more
Versant Ventures (via PR Newswire) • June 21, 2016
Northern Biologics announced its official launch and a US $10 million Series A financing co-led by founding investor Versant Ventures and Celgene Corporation. The funding was aimed at advancing its pipeline of antibody-based therapeutics for oncology and fibrosis....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Northern Biologics, are just a search away.